| A | B | C | |
|---|---|---|---|
| 1 | Main | ||
| 2 | Brand | Paxlovid, fka PF-07321332 | |
| 3 | Generic | nirmatrelvir, ritonavir | |
| 4 | Regulatory | EUA 12/2021, international Late 2021/Early 2022 | |
| 5 | Filed high-risk NDA | ||
| 6 | Economics | China Meheco Group | |
| 7 | Clinical Trials | ||
| 8 | Phase II/III "EPIC-SR" (standard risk) | ||
| 9 | PE of self-reported alleviations of symptoms for 4 consecutive days | ||
| 10 | |||
| 11 | Phase II/III "EPIC-PEDS" n=140 high-risk | ||
| 12 | |||
| 13 | Phase II/III "EPIC-PEP" household contacts | ||
| 14 | PE was not met | ||
| 15 | 32% and 37% risk reduction in adults for 5 and 10 day treatment |